Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) spanning five years over the United States' insistence on sensitive data.
This move came to light following a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative has since clarified that the US was demanding access to biological samples for research and commercial gain while refused to guarantee the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further negotiations to reach a agreement suitable to both sides so the nation's critical HIV programme can proceed.
Wider Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court suspended a related deal with the US after legal challenges were filed about the security of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and accountability.
As per statements, Sixteen African countries have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"Put simply, our country would supply the basic resources for medical research without any certainty that the end products would be available to our population should a new health crisis arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were upending structures previously established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to manage potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation might be designed in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but urged that talks must proceed given that much of the country's Aids initiatives relied on external financing.
"If technical issues arise, including those involving data governance or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it added.
The situation highlights the complex challenges between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.